JP2021137004A - 幹細胞の細胞付着・分化促進用ナノリガンド、及びこれを用いた幹細胞の細胞付着・分化を促進する方法 - Google Patents
幹細胞の細胞付着・分化促進用ナノリガンド、及びこれを用いた幹細胞の細胞付着・分化を促進する方法 Download PDFInfo
- Publication number
- JP2021137004A JP2021137004A JP2021031825A JP2021031825A JP2021137004A JP 2021137004 A JP2021137004 A JP 2021137004A JP 2021031825 A JP2021031825 A JP 2021031825A JP 2021031825 A JP2021031825 A JP 2021031825A JP 2021137004 A JP2021137004 A JP 2021137004A
- Authority
- JP
- Japan
- Prior art keywords
- nanoligand
- differentiation
- substrate
- stem cells
- cell adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 171
- 239000003446 ligand Substances 0.000 title claims abstract description 52
- 230000021164 cell adhesion Effects 0.000 title claims abstract description 39
- 230000024245 cell differentiation Effects 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000004069 differentiation Effects 0.000 claims abstract description 53
- 239000002122 magnetic nanoparticle Substances 0.000 claims abstract description 38
- 102000006495 integrins Human genes 0.000 claims abstract description 31
- 108010044426 integrins Proteins 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 239000011247 coating layer Substances 0.000 claims abstract description 17
- 239000000758 substrate Substances 0.000 claims description 163
- 230000001737 promoting effect Effects 0.000 claims description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000377 silicon dioxide Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 8
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 8
- 230000008093 supporting effect Effects 0.000 claims description 5
- 239000003929 acidic solution Substances 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 abstract description 26
- 230000002123 temporal effect Effects 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 50
- 238000010166 immunofluorescence Methods 0.000 description 37
- 238000011065 in-situ storage Methods 0.000 description 29
- 210000004940 nucleus Anatomy 0.000 description 29
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 22
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 22
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 22
- 102000007469 Actins Human genes 0.000 description 21
- 108010085238 Actins Proteins 0.000 description 21
- 238000012258 culturing Methods 0.000 description 20
- 102000012355 Integrin beta1 Human genes 0.000 description 18
- 108010022222 Integrin beta1 Proteins 0.000 description 18
- 210000000805 cytoplasm Anatomy 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 14
- 230000001464 adherent effect Effects 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000003970 Vinculin Human genes 0.000 description 11
- 108090000384 Vinculin Proteins 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011435 rock Substances 0.000 description 7
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 6
- 102000005640 Myosin Type II Human genes 0.000 description 6
- 108010045128 Myosin Type II Proteins 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- -1 maleimide-polyethylene Chemical group 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 5
- 101150111584 RHOA gene Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000030648 nucleus localization Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- 102100026508 Tafazzin Human genes 0.000 description 2
- 101710175789 Tafazzin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 238000000089 atomic force micrograph Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 2
- HOIQWTMREPWSJY-GNOQXXQHSA-K iron(3+);(z)-octadec-9-enoate Chemical compound [Fe+3].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O HOIQWTMREPWSJY-GNOQXXQHSA-K 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadec-1-ene Chemical compound CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229910017135 Fe—O Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000759453 Homo sapiens YY1-associated protein 1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229910018557 Si O Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100023267 YY1-associated protein 1 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical group [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000024155 regulation of cell adhesion Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3278—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction involving nanosized elements, e.g. nanogaps or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
- C12N5/0075—General culture methods using substrates using microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2203/00—Investigating strength properties of solid materials by application of mechanical stress
- G01N2203/02—Details not specific for a particular testing method
- G01N2203/06—Indicating or recording means; Sensing means
- G01N2203/0617—Electrical or magnetic indicating, recording or sensing means
- G01N2203/0635—Electrical or magnetic indicating, recording or sensing means using magnetic properties
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Ceramic Engineering (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
巨視的なリガンド密度の可逆的変化を引き起こせないという短所があった。
コアを包み込むように設けられ、インテグリン結合リガンドペプチドを含むコーティング層と、
コアと前記コーティング層の間に備えられるリンカーと、を含み、
インテグリン結合リガンドペプチドは、負に荷電されたことを特徴とする、幹細胞の細胞付着・分化促進用ナノリガンドを提供する。
コアをリンカーを含む第1の懸濁液と混合してリンカーが結合されたコアを製造するステップと、
リンカーが結合されたコアをインテグリン結合リガンドペプチド(RGD)を含む第2の懸濁液と混合するステップと、を含む、上述の幹細胞の細胞付着・分化促進用ナノリガンドの製造方法を提供する。
ナノリガンド提示基板に幹細胞を処理した後、外部の磁場を印加し、幹細胞の付着・分化を調整するステップと、を含む、幹細胞の付着・分化を促進する方法を提供する。
コアをリンカーを含む第1の懸濁液と混合してリンカーが結合されたコアを製造するステップと、
リンカーが結合されたコアをインテグリン結合リガンドペプチド(RGD)を含む第2の懸濁液と混合するステップと、を含む、上述の幹細胞の細胞付着・分化促進用ナノリガンドの製造方法を提供する。
[製造例]
スライド可能なナノリガンド(slidable nano−ligand)の製造
1)磁性コアの製造(MNP)
スライド可能なナノリガンドのIn situ可逆的制御のために、スライド可能なナノリガンドの磁性コアを下記のように製造した。エタノール約80mL、脱イオン水(DI)60 mL、ヘプタン140 mLをまず混合した。当該混合物に、不活性環境下で36.5 g(120mmol)のオレイン酸ナトリウム(sodium oleate)と10.8g(40mmol)の塩化鉄(III)六水和物(iron(III)chloride hexahydrate)を70℃で4時間に渡って添加した。完全に混合した後、オレイン酸鉄(iron−oleate)を含有するヘプタン層を別々に採取した。脱イオン水で洗浄した後、ヘプタンを蒸発させた。約5.7g(20mmol)のオレイン酸と200gの1−オクタデセンを混合し、乾燥したオレイン酸鉄36g(40mmol)を添加した。この混合溶液を、約5分間100℃、その後、約30分間320℃で維持した。反応後の、混合物溶液は、室温に冷却させ、永久磁石を用いて採取したものをエタノールで3回洗浄した後、磁性コアを保存するためにヘプタンに分散させた。
ヘプタンから約30mgの磁性コアナノ粒子を25mLのシクロヘキサンに分散させ、5mLのトリトン−X(Triton−X)、5mLの1−ヘキサノール、0.5mLのNH4OH、1mLの脱イオン水を順次添加した。当該混合溶液を30分間攪拌してエマルジョンを安定化させた。このエマルジョンに、12.5μLのテトラエチルオルトシリケート(TEOS)をゆっくりと添加し、10分間攪拌した。その後、6.25mLの(3−アミノプロピル)トリエトキシシラン(APTES)をエマルジョンに添加し、16時間攪拌した。反応の後、25mLのアセトンを、当該エマルジョンに迅速に添加し、永久磁石を用いて、アセトンとジメチルホルムアミド(DMF)で洗浄し、ナノ粒子を採取した。アミノ−シリカコーティングMNPを1mLのDMFに分散させた。
スライド可能なナノリガンドのナノアセンブリを完成するために、アミノ−シリカコーティングMNPをポリエチレングリコール(PEG)リンカーと順次グラフトしてナノリガンドのスライド性を向上させ、負に荷電されたRGDリガンドでグラフトした。PEGリンカーはまた、細胞の吸収を防止する役割を果たす。1mLのDMFでアミノ−シリカコーティングMNP約20mgは5mgのマレイミド−ポリ(エチレングリコール)−NHSエステル(Mal−PEG−NHS ester;Mn=5000 Da、Biochempeg)に添加し、更に2μLのN、N−ジイソプロピルエチルアミン(DIPEA)を添加した。当該懸濁液を、暗条件下で16時間攪拌した後、永久磁石を用いてDMFとジメチルスルホキシド(DMSO)で洗浄した(それぞれ3回ずつ)。1mLのDMSOでアミノ−シリカコーティングPEG化MNPを負に荷電されたチオール化RGDペプチド(CDDRGD、GL Biochem)0.5mgに添加し、0.2%DIPEAと10mMトリス(2−カルボキシエチル)ホスフィン塩酸塩(Tris(2−carboxyethyl)phosphine hydrochloride、TCEP)を続いて添加した。当該混合溶液を、暗条件下で16時間攪拌し、永久磁石を用いて採取し、水と3回DMSOで洗浄した後、基板に静電結合する前にDMSOに維持させた。
負に帯電されたチオール化RGDペプチド(CDDRGD、GL Biochem)を添加していないことを除いて、製造例1と同様の方法で「No RGD」ナノリガンドを製造した。
実施例1
スライド可能なナノリガンド、並びに当該ナノリガンドと基板との組み合わせ
上記の製造例で製造したスライド可能なナノリガンドを基板に可逆的に結合させるために、培養グレードガラスカバースリップ(culture−grade glass coverslips、22mm×22mm)を使用した。負に荷電されたスライド可能なナノリガンドを結合する前に、ガラス基板を正電荷を帯びるようにアミノ化した。基板を塩酸とメタノールの1:1混合物に30分間浸漬させ、任意の有機汚染物を除去した後、脱イオン水で3回洗浄した。当該基板を硫酸に1時間浸漬させて表面に水酸化基を活性化させ、脱イオン水で3回洗浄した。活性化された基板は、暗条件下でAPTESとエタノールの1:1混合物で1時間処理して、基板を官能基化し、アミン基を提供した。アミノ官能基化が施された基板をエタノールで3回洗浄し、100℃で1時間乾燥させた。DMSOにスライド可能なナノリガンドの懸濁液をDMSOで1:20に希釈した後、これを正に荷電されたアミノ官能基化基板に添加した。スライド可能なナノリガンドに超音波処理を施し、室温で1時間、基板に静電的に結合させた後、DMSOで3回洗浄し、脱イオン水で3回洗浄してスライド可能なナノリガンドを有する基板を得た。
実験例1
本発明によるスライド可能なナノリガンドの形態を確認するため、スライド可能なナノリガンドを対象に透過型電子顕微鏡(TEM)、動的光散乱・高角散乱環状暗視野走査透過型電子顕微鏡(HAADF−STEM)分析を行い、その結果図3及び図4に示した。
本発明によるスライド可能なナノリガンドのIn situ可逆的・時空間的制御を実証するために、スライド可能なナノリガンドを対象に走査型電子顕微鏡(SEM)で撮影し、原子間力顕微鏡(AFM)イメージングを行い、その結果を図8及び図9に示した。
本発明によるスライド可能なナノリガンドを用いた遠隔制御方法は、マクロスケールのナノリガンド提示の時空間的な可逆的調整による、幹細胞の付着の調整に及ぼす影響を確認するために、ナノリガンドのスライドのIn situ制御がインテグリン
結紮と人間の中葉幹細胞(hMSCs)の焦点付着を調整できるか否かを調べた。
本発明によるスライド可能なナノリガンドにつき、In situ時間的制御による機械感受性介在の幹細胞の分化の変化を確認するために、下記のような実験を行った。
本発明によるスライド可能なナノリガンドが、In situ制御によって体内の幹細胞の付着を空間的に調整できることを確認するために、下記のように実験を行った。
ビンキュリン、RUNX2、YAP、TAZ、p−FAK、FAK、RhoA、HuNu)を以って4℃で16時間処理し、PBSで洗浄した。上記の細胞を、2次抗体、ファロイジン(phalloidin)、DAPIで室温にて30分間処理し、PBSで洗浄した。免疫蛍光染色を施した細胞を全ての比較群に対して同じ露出条件にて共焦点顕微鏡(LSM700、Carl Zeiss)で撮像し、その後、上記のように、ImageJソフトウェアで分析した。
Claims (12)
- 磁性ナノ粒子を含むコアと、
前記コアを包み込むように設けられ、インテグリン結合リガンドペプチドを含むコーティング層と、
前記コアと前記コーティング層の間に備えられるリンカーと、を含み、
前記インテグリン結合リガンドペプチドは、負に荷電されたことを特徴とする、幹細胞の細胞付着・分化促進用ナノリガンド。 - 前記磁性ナノ粒子は、シリカが表面に結合されたことを特徴とする、請求項1に記載の幹細胞の細胞付着・分化促進用ナノリガンド。
- 前記コアと前記コーティング層との間をリンカーで連結した構造であり、
前記リンカーは、ポリエチレングリコール(PEG)系リンカーである、請求項1に記載の幹細胞の細胞付着・分化促進用ナノリガンド。 - 前記ナノリガンドは、直径が30nm〜60nmであり、前記磁性ナノ粒子は、直径が5nm〜30nmである、請求項1に記載の幹細胞の細胞付着・分化促進用ナノリガンド。
- 前記インテグリン結合リガンドペプチドは、負に荷電されたチオール化インテグリン結合リガンドペプチドを含み、
前記ナノリガンドの表面は負に荷電されている、請求項1に記載の幹細胞の細胞付着・分化促進用ナノリガンド。 - 磁性ナノ粒子を含むコアを用意するステップと、
前記コアをリンカーを含む第1の懸濁液と混合してリンカーが結合されたコアを製造するステップと、
前記リンカーが結合されたコアをインテグリン結合リガンドペプチド(RGD)を含む第2の懸濁液と混合するステップと、を含む、請求項1〜5のうちいずれか1項に記載の幹細胞の細胞付着・分化促進用ナノリガンドの製造方法。 - 請求項1〜5のうちいずれか1項に記載の幹細胞の細胞付着・分化促進用ナノリガンドを含む溶液に、表面が活性化された基板を担持して、ナノリガンド提示基板を製造するステップと、
前記ナノリガンド提示基板に幹細胞を処理した後、外部の磁場を印加し、幹細胞の付着・分化を調整するステップと、を含む、幹細胞の付着・分化を促進する方法。 - 前記ナノリガンド提示基板を製造するステップは、
基板の表面を酸性溶液に浸漬させるステップと、
浸漬済みの基板をアミノシラン溶液に担持して前記基板の表面を活性化させるステップと、
活性化された基板を室温で超音波を利用して処理するステップと、を含む、請求項7に記載の幹細胞の細胞付着・分化を促進する方法。 - 前記表面が活性化された基板は、アミノシラン溶液に基板を担持して表面を活性化させることを特徴とする、請求項7に記載の幹細胞の細胞付着・分化を促進する方法。
- 前記幹細胞の付着・分化を調整するステップは、体内及び体外に前記ナノリガンド提示基板を位置させた後、100〜700mTの磁場を12時間〜48時間印加して行う、請求項7に記載の幹細胞の細胞付着・分化を促進する方法。
- 前記幹細胞の付着・分化を調整するステップは、基板に印加される磁場の位置を変化させて行う、請求項7に記載の幹細胞の細胞付着・分化を促進する方法。
- 前記幹細胞の付着・分化を調整するステップは、基板に印加される磁場の位置を時間に応じて変化させて行う、請求項7に記載の幹細胞の細胞付着・分化を促進する方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200025477 | 2020-02-28 | ||
KR10-2020-0025477 | 2020-02-28 | ||
KR10-2020-0050356 | 2020-04-24 | ||
KR1020200050356A KR102300182B1 (ko) | 2020-02-28 | 2020-04-24 | 줄기세포의 세포 부착 및 분화 촉진용 나노리간드 및 이를 이용한 줄기세포의 세포 부착 및 분화 촉진 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021137004A true JP2021137004A (ja) | 2021-09-16 |
Family
ID=74758636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021031825A Pending JP2021137004A (ja) | 2020-02-28 | 2021-03-01 | 幹細胞の細胞付着・分化促進用ナノリガンド、及びこれを用いた幹細胞の細胞付着・分化を促進する方法 |
Country Status (3)
Country | Link |
---|---|
US (2) | US11828719B2 (ja) |
EP (1) | EP3871697A1 (ja) |
JP (1) | JP2021137004A (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022064287A (ja) * | 2020-10-13 | 2022-04-25 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 幹細胞の挙動調節用ナノコイル-基板複合体、その製造方法、及びそれを利用した幹細胞の付着及び分化調節方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170285020A1 (en) * | 2016-04-01 | 2017-10-05 | Emory University | Anti-Fouling Siloxane Polymers and Uses Related Thereto |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102029931B1 (ko) | 2016-08-10 | 2019-10-08 | 가톨릭대학교 산학협력단 | 단백질 리간드를 이용하여 유도만능줄기세포의 분화를 유도하는 각막 줄기세포 유사 세포주를 배양하는 방법 및 시스템 |
-
2021
- 2021-02-25 EP EP21159272.0A patent/EP3871697A1/en active Pending
- 2021-02-26 US US17/186,675 patent/US11828719B2/en active Active
- 2021-03-01 JP JP2021031825A patent/JP2021137004A/ja active Pending
-
2023
- 2023-06-21 US US18/339,108 patent/US20230324326A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170285020A1 (en) * | 2016-04-01 | 2017-10-05 | Emory University | Anti-Fouling Siloxane Polymers and Uses Related Thereto |
Non-Patent Citations (3)
Title |
---|
DEXTER S. H. WONG ET AL., NANO LETT., vol. 17, JPN6022006444, 24 February 2017 (2017-02-24), pages 1685 - 1695, ISSN: 0005022182 * |
HEEMIN KANG ET AL., ACS NANO, vol. 11, JPN6022038418, 25 August 2017 (2017-08-25), pages 9636 - 9649, ISSN: 0004873377 * |
HEEMIN KANG ET AL., NATURE COMMUNICATIONS, vol. 10, no. 1696, JPN6022006446, 2019, pages 1 - 14, ISSN: 0004722775 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022064287A (ja) * | 2020-10-13 | 2022-04-25 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 幹細胞の挙動調節用ナノコイル-基板複合体、その製造方法、及びそれを利用した幹細胞の付着及び分化調節方法 |
JP7251827B2 (ja) | 2020-10-13 | 2023-04-04 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 幹細胞の挙動調節用ナノコイル-基板複合体、その製造方法、及びそれを利用した幹細胞の付着及び分化調節方法 |
Also Published As
Publication number | Publication date |
---|---|
US20210270765A1 (en) | 2021-09-02 |
EP3871697A1 (en) | 2021-09-01 |
US20230324326A1 (en) | 2023-10-12 |
US11828719B2 (en) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102300182B1 (ko) | 줄기세포의 세포 부착 및 분화 촉진용 나노리간드 및 이를 이용한 줄기세포의 세포 부착 및 분화 촉진 방법 | |
US10844365B2 (en) | Systems and methods for magnetic guidance and patterning of materials | |
US10406242B2 (en) | Magnetic cells for localizing delivery and tissue repair | |
Pan et al. | Magnetic nanoparticles for the manipulation of proteins and cells | |
Zhu et al. | DNA-capped Fe 3 O 4/SiO 2 magnetic mesoporous silica nanoparticles for potential controlled drug release and hyperthermia | |
JP2010524442A (ja) | ナノ粒子を含む改善された三次元生体適合性骨格構造 | |
Samal et al. | Multilayered magnetic gelatin membrane scaffolds | |
Esfandyari et al. | Capture and detection of rare cancer cells in blood by intrinsic fluorescence of a novel functionalized diatom | |
US20230324326A1 (en) | Nano-ligand for promoting cell adhesion and differentiation of stem cells and method of promoting cell adhesion and differentiation of stem cells by using the same | |
Saei et al. | Fe 3 O 4 nanoparticles engineered for plasmid DNA delivery to Escherichia coli | |
JP2010538607A (ja) | 磁性送達デバイス | |
US11859169B2 (en) | Nano-ligand for promoting cell adhesion and regeneration of macrophages and method of promoting cell adhesion and regeneration of macrophages by using the same | |
US20220112460A1 (en) | Nanocoil-substrate complex for controlling stem cell behavior, preparation method thereof, and method of controlling adhesion and differentiation of stem cell by using the same | |
Saengruengrit et al. | Effective gene delivery into primary dendritic cells using synthesized PDMAEMA-iron oxide nanocubes | |
KR102660710B1 (ko) | 나노새틀라이트-기판 복합체 및 이를 이용한 줄기세포의 부착 및 분화 조절방법 | |
US20230210996A1 (en) | Nanosatellite-substrate complex and method of regulating macrophage adhesion and polarization using the same | |
ES2898883T3 (es) | Uso de células magnéticas para manipular células no magnéticas | |
WO2010090177A1 (ja) | 間葉系幹細胞の分化誘導方法 | |
Guo et al. | Novel surface engineered micro-needles towards bio-analytical applications | |
Pasqualini et al. | c12) United States Patent (IO) Patent No.: US 10,844,365 B2 | |
Wu et al. | Hyaluronan-modified Magnetic Hydroxyapatite Nanocrystals for Hyperthermia | |
Pan | Magnetic Nanomaterials: Design, Synthesis, and Biological Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221212 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230726 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230801 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230825 |